A roadmap for precision medicine in the epilepsies

SF Berkovic; IE Scheffer; S Petrou; N Delanty; TJ Dixon-Salazar; DJ Dlugos; I Helbig; WN Frankel; DB Goldstein; EL Heinzen; DH Lowenstein; HC Mefford; JM Parent; A Poduri; SF Traynelis

Journal article

A roadmap for precision medicine in the epilepsies

SF Berkovic, IE Scheffer, S Petrou, N Delanty, TJ Dixon-Salazar, DJ Dlugos, I Helbig, WN Frankel, DB Goldstein, EL Heinzen, DH Lowenstein, HC Mefford, JM Parent, A Poduri, SF Traynelis

Lancet Neurology | ELSEVIER SCIENCE INC | Published : 2015

DOI: 10.1016/S1474-4422(15)00199-4

Abstract

Technological advances have paved the way for accelerated genomic discovery and are bringing precision medicine clearly into view. Epilepsy research in particular is well suited to serve as a model for the development and deployment of targeted therapeutics in precision medicine because of the rapidly expanding genetic knowledge base in epilepsy, the availability of good in-vitro and in-vivo model systems to efficiently study the biological consequences of genetic mutations, the ability to turn these models into effective drug-screening platforms, and the establishment of collaborative research groups. Moving forward, it is crucial that these collaborations are strengthened, particularly thr..

View full abstract

University of Melbourne Researchers

Sam Berkovic Author

Ingrid Scheffer Author

Related Projects (2)

EPILEPSY: A 'PATIENT TO BENCH AND BACK TO PATIENT' PROGRAM ABOUT UNDERSTANDING THE CAUSES OF SEIZURE DISORDERS.

The team is comprised of neurologists, molecular geneticists, physiologists and brain imaging specialists and leads the world in the discove..

3 of 7 Epi4K: Gene discovery in 4,000 epilepsy genomes

DESCRIPTION (provided by applicant): The primary goal of the Epi4K Center Without Walls is to increase understanding of the genetic basis of..

Grants

Awarded by National Institutes of Health

Funding Acknowledgements

We thank all participants of the Epilepsy Genetics in the Era of Precision Medicine Meeting in Half Moon Bay, CA, USA, for their insight and contributions to the meeting. Authors of this manuscript were supported by grants from the US National Institute of Neurological Disorders and Stroke (U01NS077303 [DBG, ELH, HCM], U01NS077274 [DBG, SFB, DHL], U01NS077276 [SFB, DHL, DJD, IES], R37NS036654 [SFT], K23NS069784 [AP], R01NS069605 [HCM]), the Australian National Health and Medical Research Council (IES, SFB, SP), CURE (DBG), Burroughs Wellcome Fund (HCM), the German Research Foundation (HE 5415 3-1, 5-1, 6-1 [IH]), the EuroEPINOMICS framework of the Eurocore programme by the European Science Foundation (IH), and the intramural funds of the University of Kiel, Germany (IH).